Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) filed its Monthly Return for Equity Issuer for July 2026 with Hong Kong Exchanges and Clearing Ltd. on 4 August 2026. Key takeaways are as follows:

Share Capital Structure • Authorised/registered share capital remained unchanged at 6.64 billion shares, split between 258.20 million H shares and 6.38 billion A shares, each with a par value of RMB 1. • Issued H shares were steady at 258.20 million, with no treasury H shares outstanding. • Issued A shares (excluding treasury) declined by 0.28 million to 6.37 billion after a repurchase executed on 17 July 2026. Treasury A shares increased to 8.59 million.

Repurchase Activity • On 17 July 2026, Hengrui Pharma repurchased 280,000 A shares on the Shanghai Stock Exchange at RMB 53.89 per share, costing approximately RMB 15.09 million. • The repurchased shares are held as treasury stock for use in the company’s Employee Stock Ownership Schemes covering the 2022–2025 plans.

Public Float Compliance for H-Shares • Public float stood at 3.9 % of H shares, representing a market value of HK$16.08 billion. • This exceeds the HK$1.00 billion minimum market-value threshold stipulated by Hong Kong Main Board Rule 19A.28B, and the company confirmed full compliance with public float requirements as at 31 July 2026.

Capital Stability • No new shares were issued in either the H- or A-share classes during July 2026. • Total issued share count changed marginally due solely to the aforementioned A-share repurchase, underscoring a stable capital base.

Governance Note • The movements in treasury shares are aligned with previously approved A-Share Employee Stock Ownership Schemes detailed in company disclosures from 2025.

Overall, Hengrui Pharma’s July filing signals ongoing capital discipline with limited share count movements, continued adherence to Hong Kong listing rules, and active execution of share repurchases to support employee incentive plans.